Krystal Biotech, Inc. $KRYS Shares Sold by Cynosure Group LLC

Cynosure Group LLC lowered its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 59.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,406 shares of the company’s stock after selling 3,512 shares during the period. Cynosure Group LLC’s holdings in Krystal Biotech were worth $593,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC raised its position in shares of Krystal Biotech by 469.9% during the 4th quarter. SG Americas Securities LLC now owns 18,909 shares of the company’s stock worth $4,662,000 after acquiring an additional 15,591 shares in the last quarter. Handelsbanken Fonder AB raised its position in shares of Krystal Biotech by 58.4% during the 4th quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock worth $26,084,000 after acquiring an additional 39,000 shares in the last quarter. William Blair Investment Management LLC raised its position in shares of Krystal Biotech by 63.9% during the 3rd quarter. William Blair Investment Management LLC now owns 149,302 shares of the company’s stock worth $26,356,000 after acquiring an additional 58,203 shares in the last quarter. WINTON GROUP Ltd acquired a new stake in shares of Krystal Biotech during the 3rd quarter worth about $1,450,000. Finally, TD Asset Management Inc raised its position in shares of Krystal Biotech by 124.5% during the 3rd quarter. TD Asset Management Inc now owns 45,080 shares of the company’s stock worth $7,958,000 after acquiring an additional 25,000 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Buying and Selling

In related news, EVP John Charles Thomas sold 642 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total transaction of $193,903.26. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares in the company, valued at $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on KRYS. Wolfe Research began coverage on Krystal Biotech in a research report on Friday, March 27th. They set a “peer perform” rating on the stock. Weiss Ratings raised Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Guggenheim raised their target price on Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Jefferies Financial Group raised their price target on Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Finally, HC Wainwright restated a “buy” rating and set a $310.00 price target on shares of Krystal Biotech in a research note on Monday, June 1st. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $324.11.

Krystal Biotech Stock Up 2.1%

NASDAQ:KRYS opened at $324.75 on Tuesday. The stock’s 50 day moving average price is $289.72 and its 200 day moving average price is $269.02. The company has a market capitalization of $9.57 billion, a PE ratio of 43.42 and a beta of 0.53. Krystal Biotech, Inc. has a 52-week low of $127.99 and a 52-week high of $331.49.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The firm had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. As a group, sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.83 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.